Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 36(118), 2021

DOI: 10.1073/pnas.2105815118

Links

Tools

Export citation

Search in Google Scholar

Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

Journal article published in 2021 by Carmen Mirabelli, Yuping Zhang, Jesse W. Wotring, Charles J. Zhang, Sean M. McCarty, Reid Fursmidt, Yuanyuan Qiao ORCID, Tristan Frum ORCID, Carla D. Pretto, Namrata S. Kadambi, Anya T. Amin, Teresa R. O’Meara, Jason R. Spence, Jessie Huang ORCID, Konstantinos D. Alysandratos and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Significance Since its emergence in China in December 2019, SARS-CoV-2 has caused a global pandemic. Repurposing of FDA-approved drugs is a promising strategy for identifying rapidly deployable treatments for COVID-19. Herein, we developed a pipeline for quantitative, high-throughput, image-based screening of SARS-CoV-2 infection in human cells that led to the identification of several FDA-approved drugs and clinical candidates with in vitro antiviral activity.